BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lois N, Cook JA, Wang A, Aldington S, Mistry H, Maredza M, McAuley D, Aslam T, Bailey C, Chong V, Ganchi F, Scanlon P, Sivaprasad S, Steel DH, Styles C, Azuara-Blanco A, Prior L, Waugh N; EMERALD Study Group. Evaluation of a New Model of Care for People with Complications of Diabetic Retinopathy: The EMERALD Study. Ophthalmology 2021;128:561-73. [PMID: 33130144 DOI: 10.1016/j.ophtha.2020.10.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Kanclerz P, Tuuminen R, Khoramnia R. Imaging Modalities Employed in Diabetic Retinopathy Screening: A Review and Meta-Analysis. Diagnostics (Basel) 2021;11:1802. [PMID: 34679501 DOI: 10.3390/diagnostics11101802] [Reference Citation Analysis]
2 Prior L, Lois N; EMERALD Study Group. Patients views on a new surveillance pathway involving allied non-medical staff for people with treated diabetic macular oedema and proliferative diabetic retinopathy. Eye (Lond) 2022. [PMID: 35523861 DOI: 10.1038/s41433-022-02050-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ravilla T. A Holistic Perspective in Caring for People with Diabetic Retinopathy. Ophthalmology 2021;128:574-5. [PMID: 33745526 DOI: 10.1016/j.ophtha.2020.12.013] [Reference Citation Analysis]
4 Lois N, Cook J, Wang A, Aldington S, Mistry H, Maredza M, McAuley D, Aslam T, Bailey C, Chong V, Ghanchi F, Scanlon P, Sivaprasad S, Steel D, Styles C, Azuara-Blanco A, Prior L, Waugh N. Multimodal imaging interpreted by graders to detect re-activation of diabetic eye disease in previously treated patients: the EMERALD diagnostic accuracy study. Health Technol Assess 2021;25:1-104. [PMID: 34060440 DOI: 10.3310/hta25320] [Reference Citation Analysis]
5 Maredza M, Mistry H, Lois N, Aldington S, Waugh N; EMERALD Study Group. Surveillance of people with previously successfully treated diabetic macular oedema and proliferative diabetic retinopathy by trained ophthalmic graders: cost analysis from the EMERALD study. Br J Ophthalmol 2021:bjophthalmol-2021-318816. [PMID: 34083209 DOI: 10.1136/bjophthalmol-2021-318816] [Reference Citation Analysis]
6 Kanclerz P, Hecht I, Tuuminen R. Re: Lois et al.: Evaluation of a new model of care for people with complications of diabetic retinopathy: The EMERALD Study (Ophthalmology. 2021;128:561-573). Ophthalmology 2021;128:e45-6. [PMID: 34183174 DOI: 10.1016/j.ophtha.2021.05.013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Lois N; of the EMERALD Study Group. Reply. Ophthalmology 2021;128:e46-7. [PMID: 34183173 DOI: 10.1016/j.ophtha.2021.05.014] [Reference Citation Analysis]
8 Cai S, Liu TYA. The Role of Ultra-Widefield Fundus Imaging and Fluorescein Angiography in Diagnosis and Treatment of Diabetic Retinopathy. Curr Diab Rep 2021;21:30. [PMID: 34448948 DOI: 10.1007/s11892-021-01398-0] [Reference Citation Analysis]